<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Cancer Cell Line Authentication

cancer-cell-line-authenticationReview best practices in cancer cell line authentication, including a comparison of STR and SNP assays.

The Importance of Authenticating Cancer Cell Lines

Preclinical cancer research models - such as human xenograft tumors, murine homograft tumors, human and murine cell lines, and organoids - are widely used in cancer research and drug development. Since these models are used for a broad spectrum of applications, they are often heavily utilized (and shared) across labs worldwide.

Consequently, the cell lines used to establish these cancer models can quickly become contaminated, cross-contaminated, or even misidentified. The prevalence of contaminated cell lines is estimated at 20%, with the most frequent contaminant being HeLa cells, followed by T24 bladder cancer cells.

It’s been projected that $700 million (per year) in funding goes to studies employing contaminated or misidentified cell lines. These studies have an increased risk of reaching erroneous conclusions and can damage researcher reputations due to study retraction. Cell line and model misidentification also contributes to the sometimes poor reproducibility of preclinical studies.

It’s become vitally important for researchers and CROs to implement routine assays for quality control of their cultures, to validate identity and quality before establishing a tumor model. Although cell line authentication has been widely recommended for many years, contamination, cross-contamination, and misidentification remain a serious problem.

This post reviews two of the most common genomic-based assays for cell authentication: short tandem repeat (STR) and single nucleotide polymorphism (SNP) assays, their strengths and limitations, and reviews guidelines for determining identity.

STR or SNP: Choosing the Best Approach

How Does Short Tandem Repeat (STR) Testing Work?

STR testing employs primers that pick up repeated DNA segments, typically 2–6 base pairs. STR has been especially valuable for authenticating human cell lines, since the number of repeats at each genetic site varies within the human population. Therefore, STR genotyping can track genetic identification of tumors of human origin including either cell line derived or patient-derived xenografts (PDX).

The American Tissue Culture Collection (ATCC) has published robust guidelines that have standardized STR analysis for human cell line authentication.

STR Testing Limitations

One main limitation of STR assays is that they can suffer from inadequate accuracy, especially for samples of kinship or of close genetic background. This means that STR assays are intended for human cells and are not applicable for murine tumors, which originate from limited strains of inbred experimental mice and therefore lack unique markers to readily identify individual murine tumor models. STR profiling will also not distinguish between cell lines established from the same human donor.

What are Single Nucleotide Polymorphism (SNP) Assays?

While STR has traditionally been considered the gold standard of authentication, due to its limitations improved methods are now being developed. Advances in high throughput sequencing technologies have led to robust and cost-efficient SNP array profiling assays. SNP testing is increasingly being used to complement or replace STR authentication due to improved accuracy.

SNP testing relies upon the natural variation in single DNA nucleotides among individuals in a population. For instance, a SNP may replace the nucleotide cytosine (C) with thymine (T) in a specific region.

SNPs can authenticate murine cell lines as well as human tumor models, providing a key advantage compared to standard STR profiling. Mismatch repair (MMR) deficient human cell lines that can be misclassified by STR profiling can also be identified using SNPs, and testing can also:

  • Determine gender and ethnicity
  • Detect viral infection and mycoplasma contamination
  • Characterize common immunodeficient mouse strains.

Strengths and Limitations of the STR and SNP Assays

The main strengths and limitations of STR and SNP assays are compiled here for reference.

  Strengths Limitations
STR

Useful to authenticate human cell lines

Databases with known STR profiles available, allowing data from different laboratories to be compared to reference profiles. The DSMZ (Leibniz Institute) and ATCC repositories have large, online, and freely accessible collections of profiles to find profile matches

Often inadequately accurate, especially with kinship or close genetic background (e.g. not applicable for authenticating murine tumor models)

Unreliable for samples with varying levels of DNA degradation (e.g. formalin-fixed paraffin embedded (FFPE) tissues)

Cannot determine absence of interspecies cross-contamination and cannot identify chromosomal copy number aberrations

SNP

Efficient and robust next generation sequencing (NGS) arrays to authenticate tumor models

Applicable to murine as well as human tumor models

Can be adopted for quality assurance of banking and tracking tumor model collections

Determine gender and ethnicity, detect viral infection, and mycoplasma contamination

Lacking a searchable database for identifying cell lines

What Threshold of Match Probability Is Used for Determining Identity?

Interpreting authentication tests requires matching criteria to distinguish between “related” and “unrelated” samples. For instance, using the STR-based “Masters algorithm” or “Alternative Masters algorithm,” cell lines with ≥80% match are generally considered related (i.e. derived from the same patient or donor), while those with a 55–80% match require further profiling (e.g. alternate test methods).

The matching algorithm is based on comparing the number of shared alleles between two cell line samples, expressed as a percentage. An authenticated sample is selected as a “reference” profile, while the sample undergoing authentication is the “questioned” profile. The matching algorithm to determine the percent match between two cell lines is as follows:

Percent Match = number of shared alleles (in both STR profiles) ÷ total number of alleles in the questioned profile (note: homozygous alleles are counted as one allele)

When two samples have been concluded to be related (≥80% match), it must be kept in mind that the two samples may have originated from

  • The same cell line
  • Different cell lines that were derived from the same donor (e.g. different tissues of the same donor)
  • A related cell line (e.g. daughter or sister cell line) or
  • A cell line that may be misidentified or cross-contaminated.

Since genetic variations may occur in cell lines that are maintained in culture, these algorithms allow for some variation. The choice of ≥80% as a suitable threshold is based on the published work from the ATCC (the ASN-0002 Standard Workgroup). It relied on eight core loci in related cell line samples from five cell banks. These criteria allow for 98% of related cell line samples to be successfully authenticated using the matching algorithm.

In a small number of cell lines, STR profiles show a greater degree of instability, which results in a percent match of <80%. The ATCC Workgroup indicates that unrelated cell lines generally show percent matches of 55% or less. Based on this threshold, cell lines below 56% are considered unrelated and those at 56–80% are probably unrelated, although further data should be relied upon to confidently confirm or refute this conclusion.

How Often Should I Authenticate My Cell Lines?

While there are no definitive guidelines for how often cell lines should be authenticated, the following are a few factors to consider:

  • When a cell line is received from an unreliable source
  • After ten passages
  • After preparing a cell bank
  • When in doubt!

Overall, it is best to authenticate cell lines frequently and scientific journals and funding agencies are increasingly requesting this information. Presumably, there is always at least a small amount of doubt for any cell line that has not been authenticated recently.

Conclusion

With the importance of cell cultures in biomedical research, correct cell line authentication is key for generating reliable and reproducible data. However, cell line contamination, cross-contamination, and misidentification continue to be widespread problems, which are expected to expand given the increasing number of cell lines generated and the high rate of cell culture use in worldwide research laboratories.

The problem is exacerbated by significant gaps in basic quality control principles related to authentication. A routine and rigorous authentication process can help ensure your laboratory is using the correct cell lines that are in optimal health.


Related Posts